CN107184427A - A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid - Google Patents
A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid Download PDFInfo
- Publication number
- CN107184427A CN107184427A CN201710250848.3A CN201710250848A CN107184427A CN 107184427 A CN107184427 A CN 107184427A CN 201710250848 A CN201710250848 A CN 201710250848A CN 107184427 A CN107184427 A CN 107184427A
- Authority
- CN
- China
- Prior art keywords
- acid
- hyaluronic acid
- polyglutamic acid
- compound
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 89
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 84
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 229920002643 polyglutamic acid Polymers 0.000 title claims abstract description 67
- 108010020346 Polyglutamic Acid Proteins 0.000 title claims abstract description 63
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000011780 sodium chloride Substances 0.000 claims abstract description 13
- 101000585728 Homo sapiens Protein O-GlcNAcase Proteins 0.000 claims abstract description 11
- 102000046319 human OGA Human genes 0.000 claims abstract description 11
- 229940101556 human hyaluronidase Drugs 0.000 claims abstract description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 8
- 239000001110 calcium chloride Substances 0.000 claims abstract description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 7
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 claims abstract 3
- 101150055528 SPAM1 gene Proteins 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000008367 deionised water Substances 0.000 claims description 18
- 229910021641 deionized water Inorganic materials 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 8
- 230000029087 digestion Effects 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 230000001815 facial effect Effects 0.000 claims description 6
- 239000007901 soft capsule Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000007938 effervescent tablet Substances 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229940069521 aloe extract Drugs 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 239000003974 emollient agent Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 2
- 241000208690 Hamamelis Species 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000004088 foaming agent Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 229960005323 phenoxyethanol Drugs 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 7
- 230000008439 repair process Effects 0.000 abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 5
- 230000035699 permeability Effects 0.000 abstract description 3
- 230000005808 skin problem Effects 0.000 abstract description 3
- 230000002079 cooperative effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 31
- 238000012360 testing method Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- -1 pulvis Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000222122 Candida albicans Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 229940095731 candida albicans Drugs 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 108700022290 poly(gamma-glutamic acid) Proteins 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000009738 saturating Methods 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000011885 synergistic combination Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000002242 deionisation method Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710178510 Defensin-2 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
- ZGBSOTLWHZQNLH-UHFFFAOYSA-N [Mg].S(O)(O)(=O)=O Chemical compound [Mg].S(O)(O)(=O)=O ZGBSOTLWHZQNLH-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of cooperative compositions containing polyglutamic acid and hyaluronic acid and application, the composition includes the composition of following parts by weight：5 30 parts of hyaluronic acid, 1 10 parts of polyglutamic acid, 1 20 parts of compound；The compound includes recombined human hyaluronidase（PH20）, sodium chloride, calcium chloride, magnesium sulfate.Hyaluronic acid by the invention has anti-inflammatory bacteriostatic activity and moisturizing repair；Polyglutamic acid：With superpower moisture-retaining capacity, adsorptivity, biodegradability；Compound has safe and efficient percutaneous absorbability；Therefore this composition has more preferable moisturizing, antibacterial and excellent percutaneous permeability, and a variety of cooperative effects can rationally prevent and solve skin problem, make the more beautiful health of skin.
Description
Technical field
The present invention relates to skin care applications, more particularly to a kind of cooperative compositions containing polyglutamic acid and hyaluronic acid
And the preparation method of various formulations.
Background technology
It is reported that, polyglutamic acid (γ-PGA) is a kind of water-soluble, biodegradable, use microbial fermentation without toxicity
Boiomacromolecule made from method, it is a kind of sticking material, is found first in " natto ".γ-PGA are a kind of special
The natural polymer of anion, be using the glutamic acid of left and right optical activity as cell cube, through acyl between alpha-amido and γ-carboxyl
The homotype polyamide polypeptide that amine key knot is constituted, γ-PGA molecular weight is from 5 ten thousand to 2 megadaltons.Special molecule
Structure, makes it have extremely strong moisture-retaining capacity, can effectively increase the moisture-retaining capacity of skin, promotes skin health, its is superpower
Moisture-retaining capacity is better than common moisturizing ingredient, is the biotechnology NMF of a new generation.γ-PGA also have superpower simultaneously
Adsorptivity and biodegradability, catabolite are non-harmful glutamic acid, are a kind of excellent environment-friendly type macromolecule materials, can
As water-loss reducer, adsorbent for heavy metal, flocculant, sustained release agent and pharmaceutical carrier etc., in cosmetics, food, medicine etc.
Industry has very big commercial value and social value.
Modern medicine study shows that human flora's imbalance, pathogenic bacteria grow, and can cause endocrine dysfunction, in vivo poison
Element increases and can not discharged in time, and be inflamed reaction with skin surface in vivo, so that the toxin expelling burden of skin has been aggravated, when
Between it is long will endanger the function of skin, skin is unable to eupnea and metabolism, will form chloasma, acne, and skin will
Dry, lack moisture and oil, it is intense darkness without light.The hyaluronic acid of activation is without anaphylaxis by common hyaluronic acid using safety
The shearing of recombined human hyaluronidase, then by a special processing technology processing after, form activation segment, become magical
Almost " guaranteeing to cure mucocutaneous all kinds of diseases and ailments " bioactive materials.Inflammation is source of ten thousand diseases, is also the main of beauty and aging
Reason, the hyaluronic acid after activation is combined with extracellular CD44 and TLR4 acceptors, can promote mucocutaneous secretion defensin 2,
Promote mucocutaneous secretion functional component, and then suppress the inflammatory stimulus effect of inflammation and anti-endotoxin, strengthen cutaneous immunisation
The effect of power, makes skin beauty health.The recombined human hyaluronidase used simultaneously in the hyaluronic acid technique of production activation
Itself it is safe and efficient penetrating agent, it can digest the hyaluronic acid in skin, the viscosity of cytoplasm is reduced, so that temporarily
Skin barrier is opened, makes the direct rapid osmotic of nutriment to dermal layer of the skin and accelerates to spread and absorb, with efficiently oozing
Saturating absorbability, can quickly repair skin.Hyaluronic acid after activation enters after the skin corium of human body skin, makes skin and other
The hyaluronic acid synthetic quantity increase of tissue, so that the water retention property increase of skin, improves skin growth condition, be dermal collagen
The synthesis of albumen and elastomer provides superior external environment condition, it is recovered original smooth and elasticity, repairs skin sparing
Barrier, helps skin preservation moisture and nutrition, and then play effect of moisturizing reparation.
Composition containing hyaluronic acid after polyglutamic acid and activation is using it moisturizing, anti-inflammatory be antibacterial and excellent skin
Infiltrative a variety of cooperative effects can rationally prevent and solve skin problem, make the more beautiful health of skin.The synergistic combination
The health and beauty care product of for oral administration or external application, including but not limited to mouth can be made further by adding related matrix or auxiliary material in thing
Take liquid, pulvis, tablet, capsule, facial mask, lotion, emulsion, frost, cream, gel.
The content of the invention
The technical problem to be solved in the present invention be overcome the deficiencies in the prior art there is provided it is a kind of both had more preferable moisturizing,
The cooperative compositions containing polyglutamic acid and hyaluronic acid of antibacterial and excellent percutaneous permeability and the preparation method of various formulations.
In order to solve the above technical problems, the present invention is provided：
A kind of cooperative compositions containing polyglutamic acid and hyaluronic acid, it is characterised in that：The composition includes following weight
Measure the composition of part：5-30 parts of hyaluronic acid, 1-10 parts of polyglutamic acid, 1-20 parts of compound；It is saturating that the compound includes recombined human
The sour enzyme (PH20) of bright matter, sodium chloride, calcium chloride, magnesium sulfate.
The compound includes recombined human hyaluronidase (PH20), sodium chloride, calcium chloride, magnesium sulfate, each Ingredients Weight
Than for 1~2:130~160:1.5~2.5:0.5~1.0.
The compound includes recombined human hyaluronidase (PH20), sodium chloride, calcium chloride, magnesium sulfate, each Ingredients Weight
Than for 1:100:2:1.
Hyaluronic acid, polyglutamic acid, compound weight ratio are 10:5：11.
Hyaluronic acid has anti-inflammatory bacteriostatic activity and moisturizing repair after activation by the invention；Polyglutamic acid：Tool
There are superpower moisture-retaining capacity, adsorptivity, biodegradability；Enzyme of the compound comprising enzymolysis hyaluronic acid and enzymolysis environment institute
The ion needed, while the recombined human hyaluronidase used in the hyaluronic acid technique of production activation is safe and efficient in itself
Penetrating agent, it can digest the hyaluronic acid in skin, reduce the viscosity of cytoplasm, so as to temporarily open skin barrier, make
The direct rapid osmotic of nutriment is to dermal layer of the skin and accelerates to spread and absorbs, can be fast with efficient osmotic absorption
Speed repairs skin；Therefore this composition has more preferable moisturizing, anti-inflammatory antibacterial and excellent percutaneous permeability, a variety of collaboration work(
Effect can rationally prevent and solve skin problem, make the more beautiful health of skin.
Embodiment
In order to illustrate that effect and component ratio of hyaluronic acid toothpaste of the invention are properly lifted following examples and done further
Explanation.
(1) synergistic combination composition formula (part by weight)
Originally cooperative compositions composition and weight ratio containing polyglutamic acid and hyaluronic acid are：5-30 parts of hyaluronic acid, poly- paddy
1-10 parts of propylhomoserin, compound, 1-20 parts；Compound includes recombined human hyaluronidase (PH20), sodium chloride, calcium chloride, sulfuric acid
Magnesium.Various dosage form products are can be prepared by said composition addition auxiliary material.In the composition plus deionized water be made contain polyglutamic acid
With the cooperative compositions solution of hyaluronic acid.
(2) effect of each composition
Hyaluronic acid after activation：With anti-inflammatory bacteriostatic activity and moisturizing repair；
Polyglutamic acid：With superpower moisture-retaining capacity, adsorptivity, biodegradability；
Compound：Compound is made up of recombined human hyaluronidase (PH20), sodium chloride, calcium chloride, magnesium sulfate, each composition
Match as 1~2:130~160:1.5~2.5:0.5~1.0, optimum weight ratio is 1:100:2:1, while in production activation
The recombined human hyaluronidase used in hyaluronic acid technique is safe and efficient penetrating agent in itself, and it can be digested in skin
Hyaluronic acid, reduces the viscosity of cytoplasm, so as to temporarily open skin barrier, makes the direct rapid osmotic of nutriment to skin
Skin corium is simultaneously accelerated to spread and absorbed, and with efficient osmotic absorption, can quickly repair skin；
It is prepared by composition solution：Take hyaluronic acid and compound in the range of weight ratio be dissolved at 35-40 DEG C 50g go from
In sub- water, 1000-3000r/min stirring digestion 3-4h adjust pH5.0-5.6, add polyglutamic acid, plus deionized water is to 100 mixed
Close uniform, save backup.
Matrix auxiliary material：For the production of the formulations such as oral liquid, pulvis, tablet, capsule, facial mask, lotion, emulsion, frost, cream, gel
Product figuration and other effects.
(3) Efficacy experiments
First, bacteriostatic experiment
Take Clinical isolation Escherichia coli, staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans a little, connect respectively
Kind in broth bouillon, in cultivating 18h at 37 DEG C.(calf serum that 20% is added in Pseudomonas aeruginosa broth bouillon) takes
Each bacterial strain nutrient broth culture of 18h cultures, being made into bacteria suspension is used to test.Sterilizing test tubes 11, the 1st are taken respectively
Branch adds nutrient broth fluid nutrient medium 9ml, and 2-10 branch adds 5ml, and the 11st addition 10ml, separately sampled product contain polyglutamic
Acid and the cooperative compositions solution 1ml of hyaluronic acid add the 1st test tube, it is well mixed after take 5ml to add the 2nd, it is dilute successively
Release to the 10th, the 11st is not added with sample as control.Often pipe is cultivated at a temperature of adding escherichia coli suspension 0.1ml, 37 DEG C
24h, takes out observation bacterial growth situation.Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans grow with above-mentioned Germicidal efficacy
Situation.As test tube becomes cloudy, that is, bacterial growth is represented, sample is without bacteriostasis；If test tube is limpid represent bacterial growth by
Suppress.As shown in table 2, cooperative compositions solution of the present invention is to Clinical isolation Escherichia coli, golden yellow grape for experimental result
Coccus, Pseudomonas aeruginosa, Candida albicans have stronger bacteriostasis.
The bacteriostatic experiment each sample composition of table 1 is constituted
| Hyaluronic acid | Polyglutamic acid | Compound | Deionized water | |
| Sample one | 1.0% | 0.5% | 1.1% | To 100 |
| Sample two | 1.0% | — | 1.1% | To 100 |
| Sample three | 1.0% | 0.5% | — | To 100 |
| Sample four | — | 0.5% | — | To 100 |
Last limpid test tube numbering in each sample of table 2 correspondence bacteriostatic test
| Escherichia coli | Staphylococcus aureus | Pseudomonas aeruginosa | Candida albicans | |
| Sample one | 6 | 5 | 5 | 5 |
| Sample two | 4 | 3 | 3 | 3 |
| Sample three | - | - | - | - |
| Sample four | - | - | - | - |
By above-mentioned limpid broth tubes and control group transferred species broth agar plates after diluting according to a certain percentage, observation
24h, the Cmin of no bacterial growth is bacteriocidal concentration, is designated as C, and unit is mg/mL, as a result as shown in table 3, illustrates this hair
Bright cooperative compositions solution has to Clinical isolation Escherichia coli, staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans
Stronger bactericidal action；Simultaneously by contrast it can be seen that the inventive composition solution has synergy at antibacterial aspect.
The sterilization conditions of 3 embodiment of table one
| C (Escherichia coli) | C (staphylococcus aureus) | C (Pseudomonas aeruginosa) | C (Candida albicans) | |
| Sample one | 0.07 | 0.14 | 0.12 | 0.18 |
| Sample two | 0.36 | 0.65 | 0.62 | 0.71 |
| Sample three | — | — | — | — |
| Sample four | — | — | — | — |
| Control group | — | — | — | — |
Note："-" indicates no bactericidal properties.
2nd, the compound prescription of cooperative compositions is studied
The biologically active human of cooperative compositions solution, i.e. anti-inflammatory bacteriostatic activity are now detected using the method for human experimentation,
Cooperative compositions solution is studied to prevent and treat disease of skin.
All experimenters of this experiment are different degrees of disease of skin patient, and experimental group 1 is answered using polyglutamic acid 0.5%+
Smeared 1 time before being slept every night with the composition solution of thing 1.1%+ hyaluronic acids 1.0%；Experimental group 2 is saturating using polyglutamic acid 0.5%+
Sour 1.0% composition solution of bright matter is smeared 1 time before sleeping every night；Experimental group 3 uses 1.0% group of compound 1.1%+ hyaluronic acids
Polymer solution is smeared 1 time before sleeping every night；Positive control is smeared 1 time before being slept every night using 1.0% hyaluronic acid solution；Negative control
Smeared 1 time before being slept every night using physiological saline；Comparing symptom after five groups of treatments 7 days improves situation.
The symptom therapeutic evaluatioies such as dermal sensation discomfort, allergy, inflammation, peculiar smell, spot：
It is effective：Symptom is significantly improved or disappeared, patient satisfaction；Effectively：Symptom has improvement or mitigated, and patient still has discomfort,
It is required that continual cure；It is invalid：Symptom is unsatisfied with without obvious mitigation, patient.
Statistical method：Statistical procedures are carried out using SPSS12.0 statistics softwares, compared between metering and enumeration data group
Relatively examined using t and x2 is examined, with p<0.05 is statistically significant difference.
As a result it is as follows：
As shown in table 4, the 8th day symptom improves situation：Experimental group 1 effective 10, total effective rate 100%；Experimental group 2 shows
Effect 0, effective 5, invalid 5, total effective rate 50%, obvious effective rate is compared P with experimental group 1<0.01；Experimental group 3 effective 6,
Effective 4, total effective rate 100%, obvious effective rate is compared P with experimental group 1<0.01；Effective 0 of positive control is effective 2, invalid
8, total effective rate 20%, obvious effective rate is compared P with experimental group 1<0.01.
The 8th day each group patient symptom of table 4 improves situation and is compared as follows：
| Group | Sample number | It is effective | Effectively | It is invalid | Total effective rate (%) |
| Experimental group 1 | 10 | 10 | 0 | 0 | 100 |
| Experimental group 2 | 10 | 0 | 5 | 5 | 50 |
| Experimental group 3 | 10 | 6 | 4 | 0 | 100 |
| Positive control | 10 | 0 | 2 | 8 | 20 |
| Negative control | 10 | 0 | 0 | 10 | 0 |
Conclusion：
Experimental group 1 (polyglutamic acid 0.5%+ compound 1.1%+ hyaluronic acids 1.0%) is substantially than the (polyglutamic of experimental group 2
Sour 0.5%+ hyaluronic acids 1.0%), experimental group 3 (compound 1.1%+ hyaluronic acids 1.0%), positive control it is effective.This hair
Bright human experimentation shows the composition solution of (1) polyglutamic acid, compound and hyaluronic acid three composition to prevention and treatment
Disease of skin is evident in efficacy；(2) polyglutamic acid to the hyaluronic acid after activation prevention and treatment disease of skin curative effect in terms of
There is obvious synergy.
3rd, the optimum proportioning of cooperative compositions compound prescription is studied
Method：Manufacture 0.1%, 0.5%, 1.0% polyglutamic acid and 0.5%, 1.1%, 2.0% compound and
0.5%th, the cooperative compositions solution other compositions of 1.0%, 2.5% hyaluronic acid compound prescription are deionized water, Suo Youcheng
Divide percentage by weight summation 100%.All experimenters of this experiment are different degrees of disease of skin patient, test the poly- paddy of 1-30
The cooperative compositions solution of propylhomoserin, compound and hyaluronic acid various concentrations smears 1 progress Three factors-levels before sleeping every night
Orthogonal experiment；Positive control 28-30 is respectively adopted before 0.5%, 1.0%, 2.5% hyaluronic acid solution is slept every night and smears 1
It is secondary, the situation after observation treatment；31 be that 1 prevention and treatment skin disease is smeared before negative control is slept every night using physiological saline
Disease, the situation after observation treatment；Every group of 5 patients, comparison therapy symptom improvement situation after 7 days.
The orthogonal experiment factor meter of table 5：
The symptom the standard of curative effect evaluation such as dermal sensation discomfort, allergy, inflammation, peculiar smell, spot are ibid.
Statistical method：Statistical procedures are carried out using SPSS12.0 statistics softwares, compared between metering and enumeration data group
Relatively examined using t and x2 is examined, with p<0.05 is statistically significant difference.
The 8th day each group patient symptom of table 6 improves situation and is compared as follows：
Conclusion：
Through human body using test, as a result show using 0.1%, 0.5%, 1.0% polyglutamic acid and 0.5%, 1.1%,
The cooperative compositions solution of 2.0% compound and 0.5%, 1.0%, 2.5% hyaluronic acid per distribution ratio is to disease of skin
There is prevention and treatment effect, but do not limit to this scope.
4th, percutaneous absorbability is tested
The mouse skin cuticula handled well is fixed on Franz diffusion cells upwards according to Transdermal Absorption experiment, connect
30% ethanol-physiological saline is added in receives pond, is placed in the intelligent penetrating absorption instrument of water bath with thermostatic control, design temperature (37.0 ±
0.5) DEG C, rotating speed 200rmin-1.1h is balanced, sample is added after draining the bubble in reception tank.On diffusion cell supply area
Be uniformly coated with sample 1g, every group parallel 3 times, respectively 0,0.1,0.3,0.5,1.0,2.0,4.0,6.0,8.0,10.0,12.0
When draw reception liquid 1mL, and fill into the reception liquid of equality of temperature same volume.The reception liquid of absorption adds test tube after filtering, then accurately
Add 2mLCTAB test solutions, from add when timing, gently vibrate rock enough long-times, during which trying one's best avoids reaction solution from producing
Raw foam, is stood to close to 10min, then pours into reaction solution in 1cm cuvettes, and wavelength is determined during 10min in 400nm
Absorbance (A400), the transdermal absorption factor of hyaluronic acid is obtained according to the standard curve of hyaluronic acid at that wavelength.
The each sample composition of table 7 composition situation is as follows
| Hyaluronic acid | Polyglutamic acid | Compound | Deionized water | |
| Sample one | 1.0% | 0.5% | 1.1% | To 100 |
| Sample two | 1.0% | 0.5% | — | To 100 |
| Sample three | 1.0% | — | 1.1% | To 100 |
| Control group | 1.0% | — | — | To 100 |
Note："-" represents to be not added with.
Conclusion：Using hyaluronic acid transdermal absorption factor as ordinate, the time (t) is abscissa, draws the transdermal suction of hyaluronic acid
Yield-time graph, the absorptivity for as a result showing hyaluronic acid in 12h is the ＞ control groups of one ＞ samples of sample, three ＞ samples two,
Show that hyaluronic acid compositions are remarkably improved the transdermal absorption factor of hyaluronic acid；As a result show 0.5h inner skins to hyaluronic acid
Absorption it is most fast, cooperative compositions is most obvious to the effect of the transdermal absorption factor of hyaluronic acid in 0.5h.
4th, moisture retention is tested
(man 5, female 15 by the men and women 20 without disease of skin that experimental selection can be influenceed by result of the test completely
Name) tested for object, to test the moistening effect of cooperative compositions.Specific method is as follows：Each experimental subjects is in sample
Before, first with behind water cleaning experiment position, then adapt to external environment condition 30 minutes.The environmental condition of experiment is：Keep indoor temperature 22-
24 DEG C, indoor humidity 45-50%, and tested in same place.Each 10ul of sample is smeared with 2*2cm2 in inboard arm, and
Dry 1 minute.Then respectively coat 20ul ultra-pure water again at the position of smearing, with 1 point be interval (0 with after towel moisture
Minute, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes), use
The each skin surface moisture for smearing position of 825 couples of Corneometer CM is measured moistening effect.Measurement result such as table 8
Shown, unit is Corneometer value (Cv).
The each sample composition of table 8 composition situation is as follows
| Hyaluronic acid | Polyglutamic acid | Compound | Deionized water | |
| Sample one | 1.0% | 0.5% | 1.1% | To 100 |
| Sample two | 1.0% | 0.5% | — | To 100 |
| Sample three | 1.0% | — | 1.1% | To 100 |
| Sample four | — | 0.5% | 1.1% | To 100 |
| Control group one | 1.0% | — | — | To 100 |
| Control group two | — | 0.5% | — | To 100 |
| Control group three | — | — | 1.1% | To 100 |
The each sample moistening effect measurement result of table 9
| 0 point | 2 | 4 | 6 | 8 | 10 | |
| Sample one | 190.5 | 92.6 | 78.3 | 72.5 | 68.2 | 67.5 |
| Sample two | 170.6 | 79.8 | 69.3 | 55.5 | 53.9 | 53.1 |
| Sample three | 175.8 | 84.5 | 72.3 | 58.9 | 56.7 | 55.4 |
| Sample four | 167.3 | 79.8 | 66.9 | 57.4 | 52.3 | 52.0 |
| Control group one | 160.9 | 72.9 | 62.5 | 53.4 | 51.2 | 49.5 |
| Control group two | 164.8 | 75.4 | 62.7 | 54.9 | 51.8 | 48.9 |
| Control group three | 144.4 | 60.6 | 51.5 | 43.9 | 42.1 | 40.5 |
Cooperative compositions of the present invention, which is can be seen that, from upper table measurement result contrasts single polyglutamic acid, hyaluronic acid guarantor
Wet effect is more longlasting, illustrates that the polyglutamic acid in said composition and the hyaluronic acid after activation have brilliance on moistening effect
Synergy.5th, acute oral toxicity is tested
According to test basis《Disinfection technology standard》(defend method prison hair in the 3.4 of (third edition) first fascicle experimental technique specification
[1999] No. 448).By animal (regular grade NIH mouse 20, male and female half and half, 18~22g of body weight) water supply fasting 12 hours,
Distilled water is solvent, and tested material (uses weight ratio for 1:0.5：1.1 hyaluronic acid, polyglutamic acid, compound deionization are water-soluble
Liquid) dosage is set as 5500mg/kg, tested material is once filled to animal with gavage syringe needle by 0.2ml/20g body weight.After administration immediately
The poisoning manifestations, death toll and death time of animal are observed and recorded, observe secondary daily, two weeks observation periods.According to acute poison
Property grade scale carry out toxicity grading.Experimental result：In observation period, test mice does not occur manifest symptom, no dead generation.
The tested material of table 10 is to NIH chmice acute Oral toxicity result of the tests
| Sex | Dosage (mg/kg) | Number of animals (only) | Death toll (only) | The death rate (%) |
| It is female | 5500 | 10 | 0 | 0 |
| It is male | 5500 | 10 | 0 | 0 |
Conclusion：Cooperative compositions of the present invention is to the acute through LD50 ＞ 5000mg/kg, the true nontoxic level in border of NIH mouse.
6th, vaginal mucosa stimulation test
Press《Disinfection technology standard》(third edition) first fascicle《Experimental technique specification》The 3.5th in (Ministry of Public Health, 2012.4)
Carry out.Healthy White Rabbit 12 is chosen, is divided into experimental group 8, excipient group 2 and blank control group 2.Experimental group：It will apply
There is cooperative compositions test specimen of the present invention (to use weight ratio for 1:0.5：1.1 hyaluronic acid, polyglutamic acid, compound are gone
Deionized water solution) the roundlet sliver of 2.0cm length insert experimental animal intravaginal, every kind of each 2 of sample；Excipient group：With same
The sliver of sample size is soaked with sterile saline, inserts animal intravaginal；Blank group：Do not process.Sliver is removed after 4 hours,
Animal is put to death after 24 hours, topical vaginal tissue is taken out, observation whether there is the phenomenons such as hyperemia, oedema.
The sample vaginal mucosa stimulation test of table 11 is as follows：
| Symptom of erythema | Edematous condition | Stimulate the reaction is integrated | |
| Experimental group | — | — | 0 |
| Excipient group | — | — | 0 |
| Blank group | — | — | 0 |
Note："-" indicates no erythema or edematous condition；" 0 " represents no vaginal irritation reaction.
As a result show, in the observation period, test group, excipient group, blank control group animal topical vaginal tissue are to occur
Erythema or edematous condition, stimulate the reaction integral mean value are 0.According to《Disinfection technology standard》(third edition) first fascicle《Test skill
Art specification》Relevant criterion judges in (Ministry of Public Health, 2012.4), and the present invention is nonirritant to healthy White Rabbit vaginal mucosa.
(4) embodiment
1) embodiment one：Cooperative compositions solution containing polyglutamic acid and hyaluronic acid
First, it is formulated (part by weight)
2nd, preparation method (technical scheme)
A, above-mentioned formula rate hyaluronic acid and compound is taken to be dissolved in 37 DEG C in 50g deionized water, 1000r/min is stirred
Digestion 3h is mixed, pH5.5 is adjusted；
B, addition polyglutamic acid fully dissolve；
C plus deionized water are saved backup to 100 well mixed.
2) embodiment two：Cooperative compositions facial mask containing polyglutamic acid and hyaluronic acid
First, it is formulated (part by weight)
2nd, preparation method (technical scheme)
A, take the hyaluronic acid and compound of ratio in above-mentioned formula to be dissolved in 37 DEG C in 50g deionized water, 1500r/
Min stirring digestion 3h, adjust pH5.5, add polyglutamic acid and fully dissolve；
B, the addition after abundant dissolving at 35 DEG C by hydroxyethyl cellulose；
C, glycerine, butanediol, D-sorbite, soluble olive oil, polyethylene glycol 400 sequentially added into above-mentioned solution, mixed
Close uniform, fully dissolving；
D, by aloe extract, hamamelis extract, EDTA-2Na Phenoxyethanols, Sensiva SC50, essence add on
Solution is stated, is well mixed, fully dissolves；
E, tune pH are standby to 5.5.
3) embodiment three：Cooperative compositions effervescent tablet containing polyglutamic acid and hyaluronic acid
First, it is formulated (part by weight)
2nd, preparation method (technical scheme)
A, by the citric acid of ratio in above-mentioned formula under the conditions of 100 DEG C dry 2 hours, sodium acid carbonate is in 100 DEG C of conditions
Lower drying 2 hours, crushed 100 mesh sieves respectively, was well mixed, and sealing is cooled to 40 DEG C；
B, hyaluronic acid and compound is taken to be dissolved in 37 DEG C in 50g deionized water, 2000r/min stirring digestion 3h are adjusted
PH5.5, adds polyglutamic acid and fully dissolves, be spray dried to dry powder, adds a and is well mixed；
C, sodium chloride, sorbierite, peppermint, amino acid foaming agent, sodium benzoate, essence are added into above-mentioned material mix equal
Even, grinding, sealing is put in 60 DEG C of oven drying 30min；
D, the above-mentioned material of Macrogol 4000 addition that will spray ethanol solution, are well mixed, cross 140 mesh sieves, be put into pressure
Piece machine carries out tabletting, produces effervescent tablet.
4) example IV：Synergistic combination composition soft capsule containing polyglutamic acid and hyaluronic acid
First, soft capsule shell formula (part by weight)
Wherein, capsule heart formula (part by weight)
2nd, preparation method (technical scheme)
A, capsule shells preparation：The glycerine of aforementioned proportion, D-sorbite, mannitol, maltose are added into part successively
20min is stirred in water, it is slow to add gelatin and remaining water, do not stop stirring 25 minutes；Institute is added in upper gelatine solution
The pigment needed, artificial stirring 10min is uniform up to color, then stirring at low speed 40min, it is to avoid stir into bubble；By above-mentioned glue
Vacuum outgas three days at 60 DEG C, it is standby after detection is stable；
B, the capsule heart preparation：Hyaluronic acid and compound ratio in above-mentioned formula is taken to be dissolved in 50g deionized water at 37 DEG C
In, 2000r/min stirring digestion 3h adjust pH5.5, add polyglutamic acid and fully dissolve, be spray dried to dry powder, add sweet
Oil, PEG400 are well mixed and are crushed to 100 mesh, standby；
C, with soft capsule pellet processing machine pill is carried out to above-mentioned capsule shells and the capsule heart, it is standby.
5) embodiment five：Cooperative compositions private portion maintenance gel containing polyglutamic acid and hyaluronic acid
First, it is formulated (part by weight)
2nd, preparation method (technical scheme)
A, take the hyaluronic acid of percentage by weight 3.0% and 1.5% compound under the conditions of 37 DEG C, be dissolved in 50g deionization
In water, 1000r/min stirring digestion 3h adjust pH5.5, add 0.8% polyglutamic acid and fully dissolve；
B, glycerine, sodium chloride, preservative are sequentially added in above-mentioned mixed liquor, handled at 25 DEG C with 1000rmp rotating speeds
5min, is completely dissolved solution, is well mixed；
C, sequentially add carboxymethyl cellulose in above-mentioned mixed liquor, carbomer is handled at 40 DEG C with 800rmp rotating speeds
100min, is completely dissolved thickener, is well mixed；
D, a small amount of potassium hydroxide of addition, pH is to 4.8 for regulation, and gel is made.
6) embodiment six：Cooperative compositions emollient cream containing polyglutamic acid and hyaluronic acid
First, it is formulated (part by weight)
2nd, preparation method (technical scheme)
A, the carboxymethyl cellulose of above-mentioned formula rate, carbomer be added to the water successively, turned at 40 DEG C with 2000rmp
Speed processing 100min, is completely dissolved thickener, is well mixed；
B, by Trivent OCG, tristerin, B22 emulsifying agents, dimethyl silicone polymer, saualane, hydrogenation castor
Sesame oil heats consolute at 75 DEG C, it is fully melted, and is well mixed；
C, step a is slowly added to step b, and fully homogeneous, it is well mixed, 45 DEG C are cooled to；
D, hyaluronic acid and compound is taken to be dissolved in 37 DEG C in 50g deionized water, 1000r/min stirring digestion 3h are adjusted
PH5.5, adds polyglutamic acid and fully dissolves, and adds step c and is well mixed,
E, sequentially add glycerine, aloe extract, lecithin, ceramide, homogenization is well mixed it；
F, addition essence, preservative, pH is to 5.5 for regulation, standby.
Above-mentioned facial mask, effervescent tablet, soft capsule, private shield gel, emollient cream be all in configuration process first configure 50g go from
In sub- water, the Efficacy experiments data of this solution as above, behind different dosage forms product be all overall follow-up to add excipient, product
Effect is determined by hyaluronic acid, polyglutamic acid and compound.And it is also with liquid that the product of these formulations, which finally embodies effect,
What form was present.
Above-mentioned simply presently preferred embodiments of the present invention, not makees any formal limitation to the present invention.Although of the invention
It is disclosed above with preferred embodiment, but it is not limited to the present invention.Any those skilled in the art, are not taking off
In the case of from technical solution of the present invention scope, all technical solution of the present invention is made perhaps using the technology contents of the disclosure above
More possible variation and modification, or it is revised as the equivalent embodiment of equivalent variations.Therefore, it is every without departing from technical solution of the present invention
Content, according to the technology of the present invention essence to any simple modifications, equivalents, and modifications made for any of the above embodiments, all should fall
In the range of technical solution of the present invention protection.
Claims (10)
1. a kind of cooperative compositions containing polyglutamic acid and hyaluronic acid, it is characterised in that：The composition includes following weight
The composition of part：
5-30 parts of hyaluronic acid
1-10 parts of polyglutamic acid
1-20 parts of compound；
The compound includes recombined human hyaluronidase（PH20）, sodium chloride, calcium chloride, magnesium sulfate.
2. a kind of cooperative compositions containing polyglutamic acid and hyaluronic acid according to claim 1, it is characterised in that described
Compound includes recombined human hyaluronidase（PH20）, sodium chloride, calcium chloride, magnesium sulfate, each weight ratio of constituents be 1~2:130
~160:1.5~2.5:0.5~1.0, each composition optimum weight ratio is 1:100:2:1.
3. a kind of cooperative compositions containing polyglutamic acid and hyaluronic acid according to claim 1, it is characterised in that transparent
Matter acid, polyglutamic acid, compound optimum weight ratio are 10:5：11.
4. according to a kind of any described cooperative compositions solution containing polyglutamic acid and hyaluronic acid of claim 1-4, it is special
Levy and be：Composition and each component percentage by weight of the composition including following parts by weight are：
Hyaluronic acid 0.5-3.0%
Polyglutamic acid 0.1-1.0%
Compound 0.1-2.0%
Plus deionized water is to 100.
5. prepare the cooperative compositions solution methods described in claim 5, it is characterised in that comprise the following steps：Take correspondence weight
The hyaluronic acid and compound of percentage are dissolved in 50g deionized water at 35-40 DEG C, 1000-3000r/min stirring digestion 3-
4h, adjusts pH5.0-5.6, adds polyglutamic acid, plus deionized water is saved backup to 100 well mixed.
6. according to a kind of any described facial masks containing polyglutamic acid and hyaluronic acid cooperative compositions of claim 1-4, it is special
Levy and be：The facial mask includes following composition and each component percentage by weight is：
Hyaluronic acid 1.0%
Polyglutamic acid 0.8%
The % of compound 1.1
Glycerine 4.0%
Butanediol 3.0%
D-sorbite 1.0%
Soluble olive oil 1.0%
Polyethylene glycol 400 1.0%
Hydroxyethyl cellulose 0.3%
Aloe extract 0.05%
Hamamelis extract 0.05%
Phenoxyethanol 0.1%
Sensiva SC50 0.1%
EDTA-2Na 0.05%
Essence 0.1%
Plus deionized water is to 100.
7. a kind of effervescent tablet containing polyglutamic acid and hyaluronic acid cooperative compositions according to claim 1-4 is any, its
It is characterised by：The effervescent tablet includes following composition and each component percentage by weight is：
Hyaluronic acid 2.0%
Polyglutamic acid 1.0%
Compound 1.5%
Citric acid 20%
Sodium acid carbonate 20%
Sodium chloride 34%
Sorbierite 8.0%
Peppermint 5.0%
Macrogol 4000 2.0%
Amino acid foaming agent 5.0%
Sodium benzoate 0.5%
Ethanol 0.5%
Essence 0.5%.
8. a kind of soft capsule containing polyglutamic acid and hyaluronic acid cooperative compositions according to claim 1-4 is any, its
It is characterised by：The soft capsule includes following composition and each component percentage by weight is：
The capsule heart is formulated（Part by weight）
Hyaluronic acid 1.5%
Polyglutamic acid 1.0%
Compound 1.0%
Glycerine 5.0%
PEG400 28%
Excess water is mended to 100.
9. conserved according to a kind of any described private portions containing polyglutamic acid and hyaluronic acid cooperative compositions of claim 1-4 solidifying
Glue, it is characterised in that：Private portion's maintenance gel includes following composition and each component percentage by weight is：
Hyaluronic acid 3.0%
Polyglutamic acid 0.8%
Compound 1.5%
Carbomer 1.5%
Carboxymethyl cellulose 0.3%
Glycerine 1.5%
Sodium chloride 0.2%
Potassium hydroxide 0.1%
Preservative 0.1%
Balance deionized water is mended to 100.
10. a kind of emollient cream containing polyglutamic acid and hyaluronic acid cooperative compositions according to claim 1-4 is any, its
It is characterised by：The private emollient cream includes following composition and each component percentage by weight is：
Hyaluronic acid 1.0%
Polyglutamic acid 0.5%
Compound 0.8%
Trivent OCG 10%
Glycerine 6.0%
Tristerin 4.0%
B22 emulsifying agents 2.0%
Dimethyl silicone polymer 1.5%
Saualane 2.0%
Rilanit special 1.0%
Aloe extract 1.0%
Lecithin 1.0%
Carbomer 0.8%
Carboxymethyl cellulose 0.1%
Ceramide 0.1%
Essence 0.1%
Preservative 0.1%
Excess water is mended to 100.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710250848.3A CN107184427A (en) | 2017-04-17 | 2017-04-17 | A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710250848.3A CN107184427A (en) | 2017-04-17 | 2017-04-17 | A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107184427A true CN107184427A (en) | 2017-09-22 |
Family
ID=59871017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710250848.3A Pending CN107184427A (en) | 2017-04-17 | 2017-04-17 | A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107184427A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107669521A (en) * | 2017-11-14 | 2018-02-09 | 北京工商大学 | A kind of method that the bionical skin care compositions suitable for the morning and evening is prepared based on skin lipid group |
| CN107669522A (en) * | 2017-11-14 | 2018-02-09 | 北京工商大学 | A kind of method that the bionical skin care compositions suitable for youth of both sexes is prepared based on skin lipid group |
| CN108403484A (en) * | 2018-06-15 | 2018-08-17 | 广州无添加主义化妆品有限公司 | A kind of fungi polysaccharide fermentation facial mask liquid, facial mask and preparation method |
| CN109674374A (en) * | 2019-01-24 | 2019-04-26 | 宁波大学 | A kind of tearable multifunctional towel and preparation method thereof |
| CN110974749A (en) * | 2019-12-27 | 2020-04-10 | 广州市科能化妆品科研有限公司 | Soothing and repairing composition, soothing and repairing solid preparation and preparation method thereof |
| CN112089643A (en) * | 2020-09-25 | 2020-12-18 | 华熙生物科技股份有限公司 | Oral care composition containing hyaluronic acid or salt thereof |
| CN112656713A (en) * | 2020-12-25 | 2021-04-16 | 华熙生物科技股份有限公司 | Cosmetic composition containing hyaluronic acid and/or derivatives thereof, and preparation method and application thereof |
| CN113143791A (en) * | 2021-05-17 | 2021-07-23 | 威海萨维诺健康管理有限公司 | Compound injection with whitening and anti-aging effects and preparation method thereof |
| CN114129471A (en) * | 2021-12-06 | 2022-03-04 | 华熙生物科技股份有限公司 | Suspension thickening composition and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1952107A (en) * | 2006-11-16 | 2007-04-25 | 任宪君 | Natto slime hypha and its preparing method and application |
| CN105106098A (en) * | 2015-09-29 | 2015-12-02 | 新疆旺源驼奶实业有限公司 | Composition for preparing camel milk facial mask and preparation method thereof |
| CN105267234A (en) * | 2015-10-29 | 2016-01-27 | 山东省药学科学院 | Composition for relieving xerostomia and preparation method thereof |
| CN105769605A (en) * | 2016-04-25 | 2016-07-20 | 武文博 | Cosmetic containing human active hyaluronic acid or human active hyaluronate |
-
2017
- 2017-04-17 CN CN201710250848.3A patent/CN107184427A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1952107A (en) * | 2006-11-16 | 2007-04-25 | 任宪君 | Natto slime hypha and its preparing method and application |
| CN105106098A (en) * | 2015-09-29 | 2015-12-02 | 新疆旺源驼奶实业有限公司 | Composition for preparing camel milk facial mask and preparation method thereof |
| CN105267234A (en) * | 2015-10-29 | 2016-01-27 | 山东省药学科学院 | Composition for relieving xerostomia and preparation method thereof |
| CN105769605A (en) * | 2016-04-25 | 2016-07-20 | 武文博 | Cosmetic containing human active hyaluronic acid or human active hyaluronate |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107669521A (en) * | 2017-11-14 | 2018-02-09 | 北京工商大学 | A kind of method that the bionical skin care compositions suitable for the morning and evening is prepared based on skin lipid group |
| CN107669522A (en) * | 2017-11-14 | 2018-02-09 | 北京工商大学 | A kind of method that the bionical skin care compositions suitable for youth of both sexes is prepared based on skin lipid group |
| CN107669522B (en) * | 2017-11-14 | 2020-09-15 | 北京工商大学 | A method for preparing biomimetic skin care compositions suitable for young men and women based on skin lipidomics |
| CN107669521B (en) * | 2017-11-14 | 2020-10-13 | 北京工商大学 | Method for preparing bionic skin care composition suitable for morning and evening based on skin lipidomics |
| CN108403484A (en) * | 2018-06-15 | 2018-08-17 | 广州无添加主义化妆品有限公司 | A kind of fungi polysaccharide fermentation facial mask liquid, facial mask and preparation method |
| CN109674374A (en) * | 2019-01-24 | 2019-04-26 | 宁波大学 | A kind of tearable multifunctional towel and preparation method thereof |
| CN110974749A (en) * | 2019-12-27 | 2020-04-10 | 广州市科能化妆品科研有限公司 | Soothing and repairing composition, soothing and repairing solid preparation and preparation method thereof |
| CN110974749B (en) * | 2019-12-27 | 2022-05-10 | 广州市科能化妆品科研有限公司 | Soothing and repairing composition, soothing and repairing solid preparation and preparation method thereof |
| CN112089643A (en) * | 2020-09-25 | 2020-12-18 | 华熙生物科技股份有限公司 | Oral care composition containing hyaluronic acid or salt thereof |
| CN112656713A (en) * | 2020-12-25 | 2021-04-16 | 华熙生物科技股份有限公司 | Cosmetic composition containing hyaluronic acid and/or derivatives thereof, and preparation method and application thereof |
| CN113143791A (en) * | 2021-05-17 | 2021-07-23 | 威海萨维诺健康管理有限公司 | Compound injection with whitening and anti-aging effects and preparation method thereof |
| CN114129471A (en) * | 2021-12-06 | 2022-03-04 | 华熙生物科技股份有限公司 | Suspension thickening composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107184427A (en) | A kind of cooperative compositions and application containing polyglutamic acid and hyaluronic acid | |
| CN110585114B (en) | Bactericidal composition for regulating skin microbial flora and application thereof | |
| CN107714504A (en) | A kind of same human-like collagen composition and its applied in cosmetics | |
| CN107496195A (en) | A kind of recombined human hyaluronic acid compositions and its application in cosmetics | |
| CN102342993B (en) | Anti-sensitization and restoration external preparation for skin | |
| CN108143702A (en) | Efficient whitening and moisturizing mask liquid, mask and preparation method of mask liquid | |
| CN105107007B (en) | A kind of medical protective dressing of cation and preparation method thereof | |
| CN107519081A (en) | A kind of composition and preparation method that effect is repaired with anti-acne | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN110974830A (en) | External composition for preventing, relieving or treating skin allergy and application thereof | |
| CN107822945A (en) | One kind is matched unartificial yeast composition, preparation method and applied in cosmetics | |
| JPH0987189A (en) | Antiallergic agent containing isodon japonicus hara, paeonia suffruticosa andrews, perilla frutescens britton var. acuta kudo, and/or arunica montana linne | |
| CN104739749B (en) | Multiple-effect nurses one's health mask | |
| CN112972310A (en) | Composition with antibacterial and repairing effects and preparation method thereof | |
| CN111449973A (en) | Foaming agent for restoring microecological balance of female vagina and preparation method thereof | |
| CN102988230B (en) | Mineral ion shampoo and preparation method thereof | |
| KR20100039532A (en) | Hydrogel composition for healing atopy and matrix patch for healing atopy using the hydrogel composition as a matrix | |
| US20220062141A1 (en) | Personal care compositions and uses thereof | |
| CN106109264A (en) | A kind of facial treatment mask with anti-bacteria wet keeping function and preparation method thereof | |
| CN106726896A (en) | A kind of beautifying health composition with anti-inflammatory bacteriostasis efficacy and preparation method thereof | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| CN107281001A (en) | A kind of activity conditioning spraying containing hyaluronic acid and preparation method thereof | |
| CN105963243B (en) | A kind of borneol cinnamomum camphora essential oil sustained release emulsifiable paste and preparation method thereof for treating acne vulgaris | |
| CN107174535A (en) | A kind of hyaluronic acid compositions and application with the transdermal reparation effect of anti-inflammatory | |
| KR20150122983A (en) | Comsmetic composition comprising mint vinegar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170922 |